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Abstract
Purpose—Surface wipe sampling for various hazardous agents has been employed in many 
occupational settings over the years for various reasons such as evaluation of potential dermal 
exposure and health risk, source determination, quality or cleanliness, compliance, and others. 
Wipe sampling for surface residue of antineoplastic and other hazardous drugs in healthcare 
settings is currently the method of choice to determine surface contamination of the workplace 
with these drugs. The purpose of this article is to review published studies of wipe sampling for 
antineoplastic and other hazardous drugs, to summarize the methods in use by various 
organizations and researchers, and to provide some basic guidance for conducting surface wipe 
sampling for these drugs in healthcare settings.
Corresponding author: Thomas H. Connor, PhD, Division of Applied Research and Technology, National Institute for Occupational 
Safety and Health, Cincinnati, OH. tmc6@cdc.gov.
*The majority of Amy Snow’s work was completed prior to her current employment with the N.C. Department of Labor, while 
working as Amy Snow Consulting.
DISCLAIMERS
The findings and conclusions in this report are those of the author and do not necessarily represent the views of the National Institute 
for Occupational Safety and Health (NIOSH). Mention of any company or product does not constitute endorsement by NIOSH. In 
addition, citations to Web sites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their 
programs or products. Furthermore, NIOSH is not responsible for the content of these Web sites. All Web addresses referenced in this 
document were accessible as of the publication date.
The findings and conclusions in this report are those of the author and do not necessarily represent the views of FedEx Ground. 
Mention of any company or product does not constitute endorsement by FedEx Ground. In addition, citations to Web sites external to 
FedEx Ground do not constitute FedEx Ground endorsement of the sponsoring organizations or their programs or products. 
Furthermore, FedEx Ground is not responsible for the content of these Web sites. All Web addresses referenced in this document were 
accessible as of the publication date.
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the N.C. Department 
of Labor (NCDOL). Mention of any company or product does not constitute endorsement by NCDOL. In addition, citations to Web 
sites external to NCDOL do not constitute NCDOL endorsement of the sponsoring organizations or their programs or products. 
Furthermore, NCDOL is not responsible for the content of these Web sites. All Web addresses referenced in this document were 
accessible as of the publication date.
HHS Public Access
Author manuscript
J Occup Environ Hyg. Author manuscript; available in PMC 2017 September 01.
Published in final edited form as:













Methods—Recommendations on wipe sampling methodology from several government agencies 
and organizations were reviewed. Published reports on wipe sampling for hazardous drugs in 
numerous studies were also examined. The critical elements of a wipe sampling program and 
related limitations were reviewed and summarized.
Results—Recommendations and guidance are presented concerning the purposes of wipe 
sampling for antineoplastic and other hazardous drugs in the healthcare setting, technical factors 
and variables, sampling strategy, materials required, and limitations. The reporting and 
interpretation of wipe sample results is also discussed.
Conclusions—It is recommended that all healthcare settings where antineoplastic and other 
hazardous drugs are handled consider wipe sampling as part of a comprehensive hazardous drug 
‘safe handling’ program. Although no standards exist for acceptable or allowable surface 
concentrations for these drugs in the healthcare setting, wipe sampling may be used as a method to 
characterize potential occupational dermal exposure risk and to evaluate the effectiveness of 
implemented controls and the overall the safety program. A comprehensive safe-handling program 
for antineoplastic drugs may utilize wipe sampling as a screening tool to evaluate environmental 
contamination and strive to reduce contamination levels as much as possible, using the industrial 
hygiene hierarchy of controls.
Keywords
Antineoplastic drugs; hazardous drugs; surface wipe sampling healthcare settings; exposure 
assessment
INTRODUCTION
Surface wipe sampling has been used extensively in healthcare settings over the past two 
decades to determine: workplace contamination with antineoplastic drugs, the need and 
effectiveness for engineering controls, the effect of improved work practice controls, and 
what type of personal protective equipment (PPE) is required.(1–7) Similar methodology has 
been successfully employed in other occupational settings for toxic agents such as lead, 
chromium VI, beryllium, arsenic, cadmium and nickel,(8) asbestos, polychlorinated 
biphenyls, pesticides and antibiotics.(9–12) Ashley et al.(13) identify the three primary reasons 
for conducting surface wipe sampling: (1) evaluation of the potential health risk; (2) hazard 
management or evaluation of the source; and (3) hazard compliance. These authors also list 
a number of reasons for wipe sampling (Table I), most of which can be applied to healthcare 
settings.
It has been postulated that dermal uptake is the most likely route of occupational exposure to 
most hazardous drugs in healthcare settings, especially low-molecular-weight antineoplastic 
drugs.(14–17) Inhalation of aerosolized droplets or vapors and accidental hand-to-mouth 
ingestion following contact with contaminated surfaces are also possible routes of 
exposure.(18,19) OSHA states that in some cases skin absorption may be a more important 
route of exposure than inhalation and may not be noticed by the employee, especially for 
non-volatile hazardous chemicals which remain on work surfaces for long periods of 
time. (20) It is generally assumed that dermal absorption is more likely for drugs with a 
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molecular weight of <500 Daltons and less likely for those >1000 Daltons.(21,22) In addition, 
lipid soluble compounds more readily penetrate the skin than water-soluble ones and uptake 
may be enhanced by the use of carrier solvents. (22) Many of the first-generation 
antineoplastic drugs are relatively small molecules with molecular weights <500 Daltons. 
Some newer antineoplastic drugs, such as monoclonal antibodies, can have a molecular 
weight >40,000 Daltons, which presumably limit their potential for dermal uptake from 
contaminated surfaces.(23–25) Although 500 Daltons is considered the maximum molecular 
weight for effective uptake of transdermal drugs by pharmaceutical companies, it is not an 
absolute cut-off point and some drugs with molecular weights of >1000 Daltons can 
penetrate the skin, but they do so at a lower efficiency. (22) In addition, solvents in some 
pharmaceuticals, such as N,N-Dimethylacetamide may pose an additional health risk (26) or 
may enhance drug penetration of the skin. (27) It should be noted that healthcare workers, 
especially nursing personnel, often have damage to their skin from repeated hand washing 
that could facilitate uptake of drugs with higher molecular weights. (20.28.29)
The first published U.S. study of surface contamination with antineoplastic drugs was by 
McDevitt et al.(30) at Johns Hopkins Hospital. It involved one cancer drug, 
cyclophosphamide, and contamination was demonstrated in both the pharmacy and patient 
treatment areas. Around the same time, several articles were published by Sessink and 
colleagues, (31–34) based on studies conducted in the Netherlands. These studies measured 
surface concentrations of several cancer drugs by wipe sampling, including 
cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil. As in the U.S. study, 
surface contamination with these drugs was demonstrated in areas where they were prepared 
and administered to patients. These studies also documented occupational exposure (uptake 
of the drugs) based on their measurement in the urine of healthcare workers.(32–34) In 1999, 
Connor et al.(1) published a large-scale study that included three cancer hospitals in the 
United States and three in Canada. This study documented surface contamination with 
cyclophosphamide, ifosfamide, and 5-fluorouracil in the pharmacy and patient treatment 
areas, and also in areas adjacent to the pharmacy. Since publication of these initial studies, 
several studies have been published in the United States and more than 100 have been 
published worldwide, demonstrating widespread workplace surface contamination with 
antineoplastic drugs (a complete listing of these studies can be found at http://www.cdc.gov/
niosh/topics/antineoplastic/). While it was not possible to summarize the information to this 
large body of work, key elements have been selected from them in order to describe a 
framework for wipe sampling for hazardous drugs in healthcare settings.
Currently, surface wipe sampling is the method of choice to evaluate surface contamination 
within healthcare settings for antineoplastic drugs. With such a large number of studies 
published from many countries around the world, the methodology used for surface wipe 
sampling and analytical laboratory analysis for antineoplastic drugs has varied considerably. 
In the United States, several guidance documents published by government and other 
organizations on wipe sampling for chemicals other than antineoplastic drugs provide 
background information on methodology.(8,10,11,35–37) This article reviews published studies 
of surface sampling for antineoplastic drugs and summarizes the methods in use by various 
organizations and researchers. It provides minimal (basic) requirements for surface sampling 
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and general guidance for conducting wipe sampling for these drugs in healthcare and other 
settings where they are handled.
METHODS
The following is an example of a sample wipe sampling strategy for antineoplastic and other 
hazardous drugs in healthcare settings. It can be modified to meet specific needs, but it 
should include all the basic steps. The information included herein has been abstracted from 
a number of sources, and most of it is common to all protocols.
Reasons for wipe sampling
Prior to performing wipe sampling, it is important to have a clear purpose and intent 
concerning the approach to be taken and how the results will be used. Because many 
antineoplastic drugs are classified as hazardous,(19) employers may use wipe sampling when 
assessing potential workplace risks. For instance, 29 CFR 1910.132 requires employers to 
“assess the workplace to determine if hazards are present, or are likely to be present, which 
necessitate the use of personal protective equipment (PPE).” In addition, OSHA(35) 
recommends that surface wipe sampling is helpful in performing a risk assessment for 
dermal uptake of chemicals when the most likely route of exposure is not inhalation. In 
support of a risk assessment, specific reasons for conducting wipe sampling for 
antineoplastic drugs in the healthcare setting include the following:
• evaluating the efficacy of engineering or administrative controls for 
eliminating or minimizing potential drug release during the handling 
lifecycle
• preemptive screening for potential exposure of healthcare workers, before 
any concerns are raised
• compliance with workplace health standards or recommended guidelines
• support for a comprehensive safe-handling program
• Assessment of contamination before moving or performing maintenance 
on equipment
• determination of baseline surface contamination levels [e.g. at a new or 
refurbished facility]
• assessment of contamination on the outside of drug vials as received from 
manufacturers
• evaluating the efficiency of deactivation, decontamination, and cleaning 
procedures in the facility
• verification of cleanliness [e.g. following a spill or decommissioning of 
equipment].
Data obtained from surface wipe sampling are indicative not of worker exposure but of 
workplace environmental contamination as a potential source of exposure.
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When developing a wipe sampling strategy for antineoplastic drugs, one must consider 
certain factors and variables (summarized in Table II). The types, frequency of use, and 
general quantities of antineoplastic drugs used at the study site should first be reviewed, to 
aid in selecting drug to use as surrogates for overall contamination. It is also prudent to 
determine what types of questions the facility is trying to answer when conducting the wipe 
sampling. Once these are selected, the availability of sampling and analytical methodologies 
should be determined. This may require selecting and partnering with a contract or research 
laboratory. Currently there are no standards or proficiency programs for surface sampling 
and analysis for antineoplastic drugs in an occupational exposure setting. Thus, it is 
desirable to use a laboratory that is both experienced in analyzing wipe samples for 
antineoplastic drugs and that holds appropriate, quality certification and accreditation, such 
as from the American Industrial Hygiene Association Laboratory Accreditation Program 
(AIHA-LAP).(38) As an alternative, a laboratory could follow Good Laboratory Practices 
(GLPs) which are US Food and Drug Administration Regulations for Bioresearch 
Monitoring (http://www.fda.gov/downloads/.../ucm070107). The laboratory’s method 
validation process should be carefully evaluated for the specific drug or drug combinations 
that will be targeted, as this information may help determine some of the factors and 
considerations for wipe sampling. For instance, the drug recovery rate is influenced by both 
the recovery from the wipe media as well as the recovery from the specific type of surface: 
smooth (stainless steel, Formica®, glass, plastic); soft (fabric, leather); rough (carpet, 
wood); porous (vinyl, rubber); and contaminated (dirty).(13) In general, smooth, nonporous 
surfaces demonstrate a better rate of recovery, often greater than 90%. It is critical that 
contract laboratories predetermine the extraction efficiencies for each drug from each 
surface type and the wipe media, using a standardized, measured surface sampling area of 
the same material (39–40) within a range of measured surface area sizes. An extraction 
efficiency of >75% is acceptable, but >90% is preferred.(36) Some contract laboratories 
provide sampling kits for a number of antineoplastic drugs. The kits should provide the user 
with the same wipe-sample medium (swabs, wipes, etc.), wetting solution, and sample 
containers that were used for validation. Other important laboratory method validation 
factors include sample storage stability and preservation techniques, wipe-sample medium 
desorption efficiency, method selectivity and sensitivity (including the linearity of 
calibration curves, limits of detection [LODs], and limits of quantitation [LOQs]), and 
quality control measures.
Most guidelines on surface sampling (8,10,11,37) suggest sampling an area of 100 cm2 
because this is assumed to be the average surface area of the palm of the hand.(22) However, 
surface area and the surface type (smooth/coarse), along with the location and number of 
samples collected, can greatly affect the final surface concentrations and all factors should 
be included in the sampling strategy. For example, one 100-cm2 sample taken in a standard 
4-foot biological safety cabinet represents <4% of the total surface area. Therefore, some 
researchers utilize larger sampling areas, such as 500 or 600 cm2, or multiple samples from 
the same location when sampling for hazardous drugs.(31,41 If a sampling area of 100 cm2 is 
employed, it would be advisable to samples many locations (such as several areas of the 
BSC), but this could be cost-prohibitive since most testing laboratories charge by the 
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sample. A better approach would be to use a sampling size of 400 cm2, thus sampling a 
larger surface area while keeping costs down. If larger surface areas are sampled, it is 
important that the surface area size selected for wipe sampling is validated as discussed 
above or studied such that the reported concentrations may be corrected for recovery 
efficiencies to acceptable levels of statistical confidence.
After reviewing the sampling plan and procedures and a laboratory has been identified a 
number of other factors should be considered. It should be determined why the sampling is 
being done and what locations and surface area sizes are to be sampled. Next, the necessary 
equipment should be assembled, and it should be ensured that personnel are adequately 
trained and supplies are available at the site. In order to minimize variability, one person 
(such as an Environmental Health and Safety [EHS] staff member, pharmacist, or 
consultant) should be identified to collect all of the wipe samples.(10,11) This list summarizes 
the preparation and sampling steps:
• Since the wipe sampling process may result in worker exposure, 
precautions should be taken to avoid exposure such as when removing 
PPE.
• Determine that the drugs of interest are currently in use and their 
frequency of use.
• Determine if fully validated sampling and analytical methods are available 
for these drugs, and evaluate the laboratory’s quality standards and 
accreditations.
• Identify the locations that will be sampled by observing the handling 
process for the selected drugs, from the point of introduction into the work 
environment to the point of use and/or disposal. For general hazard 
assessment, focus on the top one to three most frequently touched 
locations for each unique job task, such as receiving and storage, 
preparation, transport, patient administration, and disposal. (See Table III 
for typical locations.)
• Obtain all necessary materials for the sampling (Table IV).
• Obtain and read the laboratory method–specific wipe sampling protocol.
• Record all of the sampling information including: the location/surface 
material/sample area size; sample identification number; time/date 
collected; sampler’s name; and comments.
• Don appropriate protective equipment as required: gloves, gowns, shoe 
covers, etc.
• When applicable, secure a template in position with tape; disposable, 
nonporous templates are preferable.
• For irregularly shaped objects, measure surface area to be sampled and 
delineate with tape.
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• Take digital photos or video of sampling location and/or sketch the 
location so that it can be identified later.
• Carefully remove gloves and don a clean pair of gloves.
• Add required amount of solvent or wetting agent to the surface or to the 
wiping material per laboratory guidance.
• Wipe surface according to a predetermined pattern (see Appendix for 
some examples of wipe sampling schemes).(8,42) Note that excess wiping 
of the surface can reduce recovery of the chemical being sampled.(11)
• Place wipe in a proper, pre-labeled storage container and seal its top.
• If the protocol calls for an additional wipe of the same sample location, 
repeat previous three steps.
• Don a new pair of gloves for each subsequent wipe sampling to reduce the 
potential for cross-contamination from the previous wipe sample.
• Add quality control samples (field blanks or spike samples) based on the 
requirements of the laboratory method. The recommended practice for the 
number of field blanks varies from one protocol to another, but is two for 
each 10 samples with a maximum of 10 is a workable number.(43) Also, if 
included in the protocol for the laboratory, spike several wipes with a 
known amount of the drug being analyzed for use as a control sample.
• Pack samples in a shipping container per laboratory guidance, using the 
preservation methods (such as ice packs or dry ice) specified by the 
method validation, if applicable.
• Ship or transport samples to selected laboratory for analysis.
• Follow standard chain of custody procedures.
• Although the sampling procedure may effectively remove some drugs, the 
area should be cleaned according to institution guidelines to remove any 
remaining drug residue.
• All material used for wipe sampling should be disposed of according to 
state and federal requirements.
Analysis of wipe samples
Details of the analysis of wipe samples for the presence of antineoplastic drugs are beyond 
the scope of this document. A 2003 review by Turci et al.(44) describes some of the 
analytical methods that have been employed. These have included gas chromatography 
(GC), liquid chromatography (LC), high-performance liquid chromatography (HPLC), and 
ultra-performance liquid chromatography (UPLC); all in combination with mass 
spectrometry (MS) or tandem mass spectrometry (MS/MS). Inductively coupled plasma 
mass spectrometry (ICP-MS) has been used for the analysis of total platinum in platinum-
based drugs. Liquid chromatography with mass spectrometry LC-MS/MS is the current 
method of choice for analysis of most antineoplastic drugs and does not require 
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derivatization of the drug, as GC methods do.(31) Currently, several contract laboratories 
offer services using a variety of these analytical techniques. Since there is no certification for 
laboratories that analyze antineoplastic and other hazardous drugs, it is critical to obtain 
proper validation of the methodology from the laboratory.
Reporting of results
The sensitivity of current analytical methods allows for the determination of values in the 
picogram (pg) to nanogram (ng) range. Surface-wipe sample values are typically reported as 
ng/cm2 in order to standardize results across locations and studies. Analytical laboratory 
reports should also include basic information regarding the analytical method: the LOD and 
LOQ; the absolute value of drug analyte detected in the samples; the calculated surface 
concentration, if applicable; the serial dilutions performed to determine values within the 
working range of the validated method; and the results of the analysis of quality control 
samples.
Interpretation of results
The concentration ranges reported in many studies cover several orders of magnitude, from 
picograms to micrograms, and data interpretation can be challenging. Some authors have 
suggested the use of actionable guidance levels using surface concentration percentiles 
derived from historical published data. In one such example, Merger et al (41) sampled for 
cyclophosphamide, ifosfamide, and methotrexate in 33 Canadian hospitals. They 
recommended that corrective measures should be taken for hospitals with values above the 
75th percentile. Schierl and coauthors (45) have recommended using “threshold guidance 
values” (TGVs) based on the results of sampling data from more than 100 German hospitals. 
Based on their observation, contamination values above the 75th percentile were considered 
high and that handling procedures needed to be optimized. In another German report, 
Kiffmeyer et al (46) recommended the use of the 90th percentile and suggested a guidance 
value of 0.1 ng/cm2 based on their findings for 5-fluorouracil contamination. However, such 
an approach requires a large amount of wipe sampling data which is not available in the U.S 
and suggested values would not be based on a health outcome. An approach from the 
Netherlands took into account a cancer risk assessment and levels of cyclophosphamide in 
the urine of healthcare workers in that country. (47) The recommendation was to strive for a 
surface contamination level for cyclophosphamide of < 0.1 ng.cm2. The pharmaceutical 
industry has used a method to calculate an allowable surface concentration using the drug’s 
maximum allowable dose, the 8-hour time-weighted average (TWA) air concentration, and 
the approximate surface area of a worker’s hand.(22) But for some antineoplastic agents, the 
pharmaceutical industry–derived TWA air concentration limits cannot be found on safety 
data sheets and have not been validated by an authoritative organization in the U.S.
No regulations or standards exist for allowable or acceptable antineoplastic-drug surface 
concentrations in the healthcare setting, and currently little is known about the potential 
health risks associated with low-level multidrug environmental surface contamination. 
Because of the mutagenic, teratogenic, and carcinogenic nature of many antineoplastic 
drugs, it has been suggested that occupational exposures be reduced with use of a principle 
from radiation safety: as low as reasonably achievable (ALARA) (48–50) (10 CFR 20.1003). 
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A comprehensive safe-handling program for antineoplastic drugs that adopts the ALARA 
principle may utilize wipe sampling as a screening tool to evaluate environmental 
contamination as a potential exposure source and strive to reduce contamination levels as 
much as possible, using the industrial hygiene hierarchy of controls: Elimination; 
Substitution; Engineering Controls; Administrative Controls, PPE.(51) Elimination and 
Substitution are typically not compatible with hazardous drug handling. However, with 
increasing analytical knowledge and technology and lower LODs/LOQs, it can be difficult 
to determine reasonable achievability. Although there have been several attempts to correlate 
surface contamination with uptake of the drugs in healthcare workers and/or adverse health 
effects, such correlations have not provided sufficient information that can be used 
quantitatively to set a value for surface contamination. (31,47, 52–55) Given the large number 
of drugs in use at any given time by a healthcare facility, it would not be possible to conduct 
risk assessments on all the drugs and the possibility of interactions (e.g. additivity or 
synergism) between drugs would not be possible to evaluate. Using urinary excretion data, 
one recommendation for cyclophosphamide is to keep values as low as 0.1 ng/cm2.(56) Since 
cyclophosphamide and 5-fluorouracil continue to be used in most cancer treatment facilities, 
this value may serve as a benchmark for other drugs until a better understanding of adverse 
health effects can be determined.
Limitations
It is important to caution EHS professionals, who are accustomed to interpretation of air 
sampling data, that interpretation of surface sampling results is quite different. Surface 
sampling data are best used as a screening tool but, as noted above, can be used to evaluate 
the effectiveness of engineering and administrative controls and the spread of contamination 
to other areas. Healthcare workers need to be aware that the sampling only captures a 
moment in time and that many variables such as the technique of the last person to work in 
the area, recent spills, and improper cleaning can greatly affect the sampling results. There 
are many additional variables with surface sampling and additional difficulties with 
reproducibility of sampling techniques in comparison with air sampling. Some EHS 
professionals consider surface sampling data as “semi-quantitative” or rank-ordered data, as 
compared to traditional quantitative air sampling data.(22) Comparison of data sets from 
different surveys should be limited to the same work environment (baseline, trending, post 
clean-up, etc.) and as collected by the same sampler when possible. EHS professionals 
should proceed with caution when comparing data sets across different work environments.
There are a number of other limitations to performing wipe sampling for antineoplastic 
drugs, as summarized below:
• Some drugs may not be stable in the environment or on the sampling 
materials and will be under-reported or may not be detected during 
analysis.
• Other drugs such as cyclophosphamide are very stable in the environment 
and may represent spills or other sources of contamination that have taken 
place at an earlier date (e.g., days or weeks).
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• In some instances, interferences may be caused by agents used to clean 
surfaces and other contaminates.
• If a robust sampling strategy is not developed with the sampling locations 
carefully selected or are selected at random, contamination may be missed 
and/or inappropriate conclusions may result.
• If the incorrect solvent or wetting agent is used for a specific drug, the 
sampling efficiency may be very low. The solvent or wetting agent should 
be pre-determined by the testing laboratory.
• If the wipe sampling is not performed correctly, the amount of drug 
recovered may be low.
• Collecting too few samples may lead to problems with characterizing 
potential sources of surface contamination.
• No accepted standards are available for these drugs for surface 
contamination in healthcare settings, but, wipe sampling can be utilized to 
determine if a drug is present, and the effectiveness of engineering and 
administrative controls.
• The data obtained from surface wipe sampling is not an indication of 
workplace exposure but an indication of workplace environmental 
contamination as a potential source of exposure.
CONCLUSIONS
Dermal absorption has been suggested as the most likely route of exposure to antineoplastic 
drugs in the healthcare setting, especially low-molecular-weight drugs. Surface wipe 
samples for antineoplastic and other hazardous drugs from potentially contaminated surfaces 
in healthcare facilities and other areas where they are used may be evaluated by occupational 
health professionals to determine the effectiveness of existing controls and potential health 
risks from exposure to these drugs. However, if sampling is done incorrectly or without 
proper knowledge of the potential pitfalls, then the results may be misleading.
In U.S. healthcare facilities, there are no dermal exposure limits for allowable levels of 
surface contamination with antineoplastic. The ALARA principle has been suggested as a 
strategy to employ as part of a comprehensive safe handling program, but with increasing 
analytical capabilities it can be difficult to assign reasonable achievability. On the basis of 
the numerous published reports in healthcare settings, it is possible to ascertain if 
contamination levels are relatively low or high, compared with values reported for other 
institutions. USP Chapter <797> recommends an ‘action level’ of 1.0 ng/cm2 for 
cyclophosphamide, but a recommendation to keep values as low as 0.1 ng/cm2 would seem 
to be a reasonably achievable goal.(46,56)
Surface sampling for antineoplastic/hazardous drugs should be a part of a comprehensive 
hazardous drug program. Each organization should carefully consider how surface sampling 
fits into its comprehensive hazardous drug program. It may help characterize potential 
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dermal exposure risk in different areas in the facility and it may help evaluate the 
effectiveness of the overall program.
Acknowledgments
The authors would like to thank Shelley Rae Carry, Kaiser Permanente for her valuable assistance in developing this 
manuscript and Seleen S. Collins, technical writer Education and Information Division, NIOSH. The authors would 
also like to thank Kevin Ashley and Teresa Lane for their review of the manuscript.
References
1. Connor TH, Anderson RW, Sessink PJM, Broadfield L, Power LA. Surface contamination with 
antineoplastic agents in six cancer treatment centers in the United States and Canada. Am J Health-
Syst Pharm. 1999; 56:1427–1432. [PubMed: 10428450] 
2. Connor TH, DeBord G, Pretty JR, et al. Evaluation of antineoplastic drug exposure of health care 
workers at three university-based US cancer centers. J Occup Environ Med. 2010; 52:1019–1027. 
[PubMed: 20881620] 
3. Wick C, Slawson MH, Jorgenson JA, Tyler LS. Using a closed-system protective device to reduce 
personnel exposure to antineoplastic agents. Am J Health-Syst Pharm. 2003; 60:2314–2320. 
[PubMed: 14652980] 
4. Harrison BR, Peters BG, Bing MR. Comparison of surface contamination with cyclophosphamide 
and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. 
Am J Health-Syst Pharm. 2006; 63:1736–1744. [PubMed: 16960258] 
5. Sessink PJM, Connor TH, Jorgenson JA, Tyler TG. Reduction in surface contamination with 
antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-
system drug transfer device. J Oncol Pharm Pract. 2011; 17:39–48. [PubMed: 20156932] 
6. Sessink PJM, Trahan J, Coyne JW. Reduction in surface contamination with cyclophosphamide in 
30 US hospital pharmacies following implementation of a closed-system drug transfer device. Hosp 
Pharm. 2013; 48:204–212. [PubMed: 24421463] 
7. Sessink PJM, Leclercq GM, Wouters DM, Halbardier L, Hammad C, Kassoul N. Environmental 
contamination, product contamination and workers exposure using a robotic system for 
antineoplastic drug preparation. J Oncol Pharm Pract. 2014 Epub ahead of print. 
8. Brookhaven National Laboratory. IH75190: Surface Wipe Sampling Procedure. Upton, NY: 
Brookhaven National Laboratory, Safety & Health Services Division, Industrial Hygiene Group; 
2014. 
9. Ness, SA. Surface and Dermal Monitoring for Toxic Substances. New York: Van Nostrand 
Reinhold; 1994. 
10. EPA. A Literature Review of Wipe Sampling Methods for Chemical Warfare Agents and Toxic 
Industrial Chemicals. Washington, DC: U.S. Environmental Protection Agency, Office of Research 
and Development; 2007. EPA/600/R-07/004
11. ASTM. D6661-10: Standard Practice for Field Collection of Organic Compounds from Surfaces 
Using Wipe Sampling. West Conshohocken, Penn: ASTM International; 2010. 
12. Nygren O, Lindahl R. Development of a method for screening spill and leakage of antibiotics on 
surfaces based on wipe sampling and HPLC-MS/MS analysis. J ASTM Intl. 2011; 8(6)
13. Ashley K, Brisson MJ, White KT. Review of standards for surface and dermal sampling. J ASTM 
Intl. 2011; 8(6)
14. Kromhout H, Hoek F, Uitterhoeve R, et al. Postulating a dermal pathway for exposure to 
antineoplastic drugs among hospital workers: applying a conceptual model to the results of three 
workplace surveys. Ann Occup Hyg. 2000; 44:551–560. [PubMed: 11042258] 
15. Fransman W, Vermeulen R, Kromhout H. Occupational dermal exposure to cyclophosphamide in 
Dutch hospitals: A pilot study. Ann Occup Hyg. 2004; 48:237–244. [PubMed: 15059800] 
16. Fransman W, Vermeulen R, Kromhout H. Dermal exposure to cyclophosphamide in hospitals 
during preparation, nursing and cleaning activities. Int Arch Occup Health. 2005; 78:403–412.
Connor et al. Page 11













17. Hon CY, Teschke K, Demers PA, Venners S. Antineoplastic drug contamination on the hands of 
employees working throughout the hospital medication system. Ann Occup Hyg. 2014; 58:1–10.
18. NIOSH. [accessed May 27, 2015] Personal Protective Equipment for Health Care Workers Who 
Work with Hazardous Drugs. 2009. DHHS (NIOSH) Publication No. 2009-106Available at http://
www.cdc.gov/niosh/docs/wp-solutions/2009-106/
19. NIOSH. [accessed May 27, 2015] NIOSH List of Antineoplastic and Other Hazardous Drugs in 
Healthcare Settings. 2014. Available at http://www.cdc.gov/niosh/docs/2014-138/
20. [accessed November 2, 2015] Surface Contaminants, Skin Exposure, Biological Monitoring and 
Other Analyses. Section II, Chapter 2. https://www.osha.gov/dts/chemicalsampling/data/
CH_235600.html
21. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of compounds and drugs. 
Exp Dermatol. 2000; 9:165–169. [PubMed: 10839713] 
22. Kimmel TA, Sussman RG, Ku RH, Adar AW. Developing acceptable surface limits for 
occupational exposure to pharmaceutical substances. J ASTM Intl. 2011; 8(8) [accessed November 
6, 2015] doi:10.1520JAI103480. http://www.usp.org/pdf/EN/referenceStandards/msds/
1601485.pdf. 
23. Halsen G, Krämer I. Assessing the risk to health care staff from long-term exposure to anticancer 
drugs: the case of monoclonal antibodies. J Oncol Pharm Pract. 2011; 17:68–80. [PubMed: 
20667850] 
24. Connor, TH.; MacKenzie, BM. [accessed May 27, 2015] Should monoclonal antibodies and their 
conjugates be considered occupational hazards?; Saf Consid Oncol Pharm Special edition. Fall. 
2011 p. 13-16.Available at www.ppme.eu
25. Alexander M, King J, Bajel A, et al. Australian consensus guidelines for the safe handling of 
monoclonal antibodies for cancer treatment by healthcare personnel. Intern Med J. 2014; 44:1018–
1026. [PubMed: 25302720] 
26. USP. [accessed November 23, 2015] Safety Data Sheet. N,N-Dimethylacetamide. http://
static.usp.org/pdf/EN/referenceStandards/msds/1601500.pdf
27. Munro DD, Stoughton RB. Dimehtylacetamide (DMAC) and dimethylformamide (DMFA) effect 
on percutaneous absorption. Arch Dermatol. 1965; 92:585–586. [PubMed: 5844405] 
28. Health and Safety Executive. Work-Related Contact Dermatitis in the Health Services. London, 
UK: Health and Safety Executive; no date. Available at http://www.hse.gov.uk/skin/employ/
highrisk/healthcare.htm [accessed July 20, 2015]
29. Kedrowski DA, Waeshaw EM. Hand dermatitis: a review of clinical features, diagnosis, and 
management. Dermatol Nurs. 2008; 20:17–25. [PubMed: 18380292] 
30. McDevitt JJ, Lees PSJ, McDiarmid MA. Exposure of hospital pharmacists and nurses to 
antineoplastic agents. J Occup Med. 1993; 35:57–60. [PubMed: 8423505] 
31. Sessink PJM, Anzion RB, Van den Broek PHH, Bos RP. Detection of contamination with 
antineoplastic agents in a hospital pharmacy department. Pharm Wkly (Sci). 1992; 14:16–22.
32. Sessink PJM, Van de Kerkhof MCA, Anzion RB, Noordhoek J, Bos RP. Environmental 
contamination and assessment of exposure to antineoplastic agents by determination of 
cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important 
exposure route? Arch Environ Health. 1994; 49:165–169. [PubMed: 8185386] 
33. Sessink PJM, Friemèl NSS, Anzion RBM, Bos RP. Biological and environmental monitoring of 
occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ 
Health. 1994; 65:401–403. [PubMed: 8034364] 
34. Sessink PJM, Wittenhorst BCJ, Anzion RBM, Bos RP. Exposure of pharmacy technicians to 
antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health. 
1997; 52:240–244. [PubMed: 9169636] 
35. OSHA. OSHA Technical Manual. Washington, DC: OSHA; 2002. Sampling for surface 
contamination. Section II, Chapter 2. 
36. OSHA. Evaluation Guidelines for Surface Sampling Methods. Salt Lake City, Utah: OSHA Salt 
Lake Technical Center; 2001. 
Connor et al. Page 12













37. NIOSH. NIOSH Manual of Analytical Methods (NMAM), Fourth Edition, 8/15/94. Cincinnati, 
OH: Centers for Disease Control and Prevention, National Institute for Occupational Safety and 
Health; 1994. Lead in Surface Wipe Samples: Method 9100. 
38. American Industrial Hygiene Association. AIHA’s Laboratory Accreditation Programs, LLC. Falls 
Church, Va: AIHA; 2015. Available at http://www.aihaaccreditedlabs.org/ [accessed May 27, 
2015]
39. Pretty JR, Connor TH, Spasojevic I, et al. Sampling and mass spectrometric analytical methods for 
five antineoplastic drugs in the healthcare environment. J Oncol Pharm Pract. 2010; 18:23–36. 
[PubMed: 21183556] 
40. B’Hymer C, Connor TH, Stinson D, Pretty J. Validation of an HPLC-MS/MS and wipe procedure 
for mitomycin C contamination. J Chromatogr Sci. 2015; 53:619–624. [PubMed: 25129062] 
41. Merger D, Tanguay C, Langlois E, Lefebvre M, Bussieres JF. Multicenter study of environmental 
contamination with antineoplastic drugs in 33 Canadian hospitals. Int Arch Occup Environ Health. 
2014; 87:307–313. [PubMed: 23471647] 
42. Hollands, W.; Siegerman, H.; Strauss, M. [accessed May 27, 2015] How to succeed in the search 
for nothing: effective swabbing techniques for cleaning validation. Controlled Environments. 2007. 
Available at http://www.cemag.us/articles/2007/02/how-succeed-search-nothing-effective-
swabbing-techniques-cleaning-validation
43. NIOSH. [accessed May 27, 2015] NIOSH Manual of Analytical Methods. 2003. Available at http://
www.cdc.gov/niosh/docs/2003-154/
44. Turci R, Sottani C, Spagnoli G, Minoia C. Biological and environmental monitoring of hospital 
personnel exposed to antineoplastic agent: a review of analytical methods. J Chromatog B. 2003; 
789:169–209.
45. Schierl R, Bohlandt A, Nowak D. Guidance values for surface monitoring of antineoplastic drugs 
in German pharmacies. Ann Occup Hyg. 2009; 53:1–9. [PubMed: 18948546] 
46. Kiffmeyer T, Tuerk J, Hahn M, et al. Application and assessment of a regular environmental 
monitoring of the antineoplastic drug contamination level in pharmacies: the MEWIP project. Ann 
Occup Hyg. 2013; 57:444–455. [PubMed: 23125441] 
47. Sessink PJM, Kroese ED, van Kranen HJ, Bos RP. Cancer risk assessment for health care workers 
occupationally exposed to cyclophosphamide. Inter Arch Occup Environ Health. 1993; 67:317–
323.
48. Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J 
Health-Syst Pharm. 1996; 53:2713–2723. [PubMed: 8931813] 
49. Zeedijk M, Greijdanus B, Steenstra FB, Uges DRA. Monitoring exposure to cytotoxics on the 
hospital ward: measuring surface contamination of four different cytotoxic drugs from one wipe 
sample. Eur J Hosp Pharm Sci. 2005; 11:18–22.
50. Polovich, M.; Bolton, DL.; Eisenberg, S., et al. Safe handling of hazardous drugs. 2. Pittsburgh: 
Oncology Nursing Society; 2011. 
51. NIOSH. [accessed May 27, 2015] Hierarchy of Controls. 2015. Available at http://www.cdc.gov/
niosh/topics/hierarchy/
52. Villarini M, Dominici L, Piccinini RR, et al. Assessment of primary, oxidative and excision 
repaired DNA damage in hospital personnel handling antineoplastic drugs. Mutagenesis. 2011; 
26:359–369. [PubMed: 21112930] 
53. Sottani C, Porro B, Cornelli M, Imbriani M, Minoia CC. An analysis to study trends in 
occupational exposure to antineoplastic drugs among health care workers. J Chromatog B. 2010; 
878:2593–2605.
54. Yoshida J, Koda S, Nishida S, Yoshida T, Miyajima K, Kumagai S. Association between 
occupational exposure levels of antineoplastic drugs and work environment in five hospitals in 
Japan. J Oncol Pharm Practice. 2011; 17:29–38.
55. Sabatini L, Barbieri A, Lodi V, Violante FS. Biological monitoring of occupational exposure to 
antineoplastic drugs in hospital settings. Med Lav. 2012; 103:394–401. [PubMed: 23077799] 
56. Sessink, PJM. [accessed May 27, 2015] Environmental contamination with cytostatic drugs: past, 
present, future. Saf Consid Oncol Pharm. Fall. 2011 Special editionAvailable at www.ppme.eu
Connor et al. Page 13













Appendix. Examples of Schemes used for Surface Wipe Sampling
FIGURE 1. 
An Example for a Scheme for Wipe Sampling with Filter Paper (8)
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An Example of a Scheme for Wipe sampling with a swab. (Modified from Hollands et 
al. (38)
TABLE I
Reasons for Conducting Surface Wipe Sampling (12)




Selection of engineering controls
Evaluation of engineering and administrative/work practice controls
Evaluation of exposure pathways
Selection of personal protective equipment
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Technical Factors and Variables to Consider when Doing Surface Wipe Sampling
Validated sampling and analytical methods
Solubility of drug in extraction solvent
Type of wipe sampling material
Extraction efficiency of drug from surface material
Recovery of drug from sampling material
Extraction solvent
Limit of detection (LOD)
Limit of quantification (LOQ)
Compatibility of extraction solvent with solvent system used for analysis
Drugs currently in use at the study site
Design and layout of area to be sampled
Number of samples to be taken
Locations to be sampled
Size of samples to be taken
TABLE III





Floor in front of BSC or CACI
Floor in pharmacy





Door handles, door knobs, other high-touch areas
Computer keyboard/mouse
Nursing and patient areas
Nurses’ station
Storage area for IV bags
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Furniture in patient room
Infusion pump
Door handles, door knobs, other high-touch areas
Computer keyboard/mouse
Floor in patient room
Floor in restroom
Notes: BSC, biological safety cabinet; CACI, compounding aseptic containment isolator; IV, intravenous.
TABLE IV




Solvent or wetting agent
Device for applying solvent (pipette)
Wipes or swabs
Sample container for wipes
Disposable gloves
Container to store samples
Container for waste materials
Notebook/laptop/tablet with chart
Digital camera
Connor et al. Page 17
J Occup Environ Hyg. Author manuscript; available in PMC 2017 September 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
